Erlotinib-induced episcleritis in a patient with pancreatic cancer

Journal of the Pancreas

Volumn 9, Issue 2, 2008, Pages 216-219

  Shahrokni, Armin ^a   Matuszczak, Justyna ^a   Rajebi, Mohammad Reza ^a   Saif, Muhammad Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies, monoclonal; Cetuximab; Erlotinib; Pancreatic neoplasms; Protein kinase inhibitors; Protein tyrosine kinase; Receptor, epidermal growth factor

Indexed keywords

CAPECITABINE; DOCETAXEL; ERLOTINIB; GEMCITABINE; OXALIPLATIN; STEROID;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CAUCASIAN; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISCLERITIS; EYE PAIN; EYELID ERYTHEMA; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; OPHTHALMOLOGY; PANCREAS CANCER; PANCREATICODUODENECTOMY; RASH; RECURRENT CANCER; SENSORY NEUROPATHY; TREATMENT DURATION; TUMOR FLARE; UNSPECIFIED SIDE EFFECT;

CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; SCLERITIS;

EID: 42949129072     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6.
3. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
5. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-46.
6. Green MR, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. J Invest Dermatol 1985; 85:239-45.
7. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007; 23:63-5.
8. Segaart S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor. inhibitors. Ann Oncol 2005; 16:1425-33.
9. Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy 2006; 26:853-67.